Competitor Landscape: Spondyloarthritis
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Scope
The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures & detailed tables
‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided
Key Highlights
Given that only 187 patients are currently enrolled in upadacitinib’s Phase II/III SELECT-Axis 1 trial in AS, it is assumed that AbbVie will need to run a Phase III program before filing
Secukinumab’s EU label update for PsA will bring it in-line with its US label, and is expected to become a key point of differentiation
Change in primary completion date of the Phase III COAST-X trial is not expected to influence ixekizumab’s regulatory timeline in any way, with Lilly stating that it expects to file for regulatory approval of ixekizumab in AS and nr-axSpA, simultaneously, by YE 2018
Reasons to Buy
Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts
AbGenomics
Abivax
Ablynx
ACEA Biosciences
Acerta Pharma
Akari Therapeutics
Akros Pharma
Almirall
Amgen
Asana Biosciences
Astellas
AstraZeneca
Bayer
Biocad
Bird Rock Bio
Boehringer Ingelheim
Bristol-Myers Squibb
Can-Fite Biopharma
Celgene
Chemo-Centryx
Cyclacel
Daichii Sankyo
Eddingpharm
Eisai
Eli Lilly
EMD Serono
Ensemble Therapeutics
Galapagos
Genentech
Gilead
GSK
Hanmi
Hoffmann-La Roche
Hutchison Medi Pharma
Innate Pharma
Innocare Pharma
Istesso
Izana Bioscience
Janssen
Japan Tobacco
Jiangsu HengRui
Kineta
Kyowa Hakko Kirin
Leo Pharma
Lupin
MacroGenics
MedImmune
Merck
Merck KGaA
Mesoblast
Momenta
MorphoSys
Morphotek
MSD
Nektar Therapeutics
Novartis
NovImmune
Noxopharm
Nuevolution
Oscotec
OSE Immuno Therapeutics
Pfizer
Philogen
Principia Biopharma
Protalex
Reata Pharmaceuticals
Regen BioPharma
Regeneron
Rigel
Rottapharm Biotech
R-Pharm
Sanofi
Sareum
Sun Pharma
Swedish Orphan Biovitrum
SynAct Pharma
Taiho
Taisho
Takeda
TiGenix
UCB
Valeant
Viela Bio
Vitae Pharmaceuticals
Vitaeris
WuXi
Xencor
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.